Welcome to our dedicated page for Reviva Pharmaceutcls Hldgs news (Ticker: RVPH), a resource for investors and traders seeking the latest updates and insights on Reviva Pharmaceutcls Hldgs stock.
Reviva Pharmaceuticals Holdings Inc (RVPH) focuses on developing novel therapies for central nervous system disorders and cardiometabolic diseases through its proprietary drug discovery platform. This page provides investors and industry observers with timely updates on clinical developments, regulatory milestones, and corporate announcements.
Access comprehensive coverage of Reviva's progress including clinical trial results, regulatory submissions, and strategic partnerships. Our curated news collection enables efficient tracking of the company's lead candidates like Brilaroxazine (RP5063) and RP1208 through critical development phases.
Key updates include progress in neuropsychiatric drug development, intellectual property advancements, and financial reporting. The resource serves investors requiring detailed insights into therapeutic pipeline maturation and market positioning within competitive CNS/pharma sectors.
Bookmark this page for streamlined access to Reviva's latest developments. Check regularly for authoritative reporting on clinical data releases, FDA communications, and research collaborations that shape the company's trajectory in biopharmaceutical innovation.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) will host a webinar on May 2, 2023, at 11:00 AM ET featuring KOL Larry Ereshefsky, PharmD, discussing brilaroxazine (RP5063), a serotonin-dopamine modulator in late development for schizophrenia. The event will cover the unmet medical need in schizophrenia treatment and Reviva's clinical trial data, including the ongoing RECOVER Phase 3 trial. Brilaroxazine has exhibited significant efficacy in a Phase 2 study, demonstrating improvements in PANSS total scores and meeting safety endpoints. Furthermore, it has potential for use in other neuropsychiatric and pulmonary conditions, having received Orphan Drug Designation from the FDA for certain indications. This webinar aims to provide insights on the treatment landscape and sustainable advancements in psychiatric and inflammatory therapies.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) announced that its Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will present a poster at the 78th Annual Scientific Convention of the Society of Biological Psychiatry from April 27-29, 2023, in San Diego, CA. The presentation, titled "Brilaroxazine (RP5063), a novel serotonin-dopamine stabilizer, displays antipsychotic efficacy in rodents," will take place on April 29, 2023, from 5:00-7:00 PM PT.
Brilaroxazine is a drug candidate showing significant clinical promise for treating schizophrenia and related disorders. In Phase 2 studies, it met primary endpoints, demonstrating efficacy with no adverse effects on weight or metabolic parameters. Additionally, it has potential applications in pulmonary diseases like PAH and IPF, having received Orphan Drug Designation from the FDA. Reviva aims to pursue further development of brilaroxazine for various neuropsychiatric conditions.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) will feature on The RedChip Money Report® on Bloomberg TV on April 22, 2023, at 7 p.m. ET. The interview includes insights from CEO Laxminarayan Bhat regarding the Company’s Phase 3 trial for schizophrenia and promising safety and efficacy results from the Phase 2 study. Reviva’s focus is on developing next-generation therapeutics to address unmet medical needs, with ongoing research on drug candidates like brilaroxazine (RP5063) and RP1208. Reviva holds composition of matter patents for both candidates in the U.S. and Europe. The RedChip Money Report® aims to provide investors with valuable information on small-cap investing and features various financial insights.
FAQ
What is the current stock price of Reviva Pharmaceutcls Hldgs (RVPH)?
What is the market cap of Reviva Pharmaceutcls Hldgs (RVPH)?
